U.S. Chronic Wound Care Market Size, Share & Industry Analysis, By Type (Diabetic Foot Ulcers, Pressure Ulcers, Venous Leg Ulcers, and Others), By Product (Advanced Wound Dressings, Wound Care Devices, Active Therapy, and Others), By End User (Hospitals & Wound Clinics and Homecare Settings & Others), and Country Forecast, 2024-2032

The U.S. chronic wound care market size was worth USD 4.43 billion in 2023 and is projected to grow at a CAGR of 6.8% during the forecast period. 

The surging prevalence of chronic diseases, such as diabetes, systemic illness, and others is one of the predominant factors increasing the risk of developing hard-to-heal wounds, such as venous leg ulcers, pressure ulcers, and others. Furthermore, the demand for chronic wound care products will surge in the forecast period owing to the rising prevalence of chronic diseases and associated complications among the geriatric population.

Due to restricted and limited mobility, old-aged people are more prone to develop chronic wounds such as pressure ulcers.

• For instance, according to the report published by the Administration for Community Living, the number of people aged 65 years and above living in the U.S. was about 54.1 million in 2019 and was anticipated to reach 80.8 million in 2040.


• Furthermore, according to an article published in NCBI in 2021, pressure ulcers affect approximately 1 million to 3 million people annually in the U.S.

Moreover, factors such as rising awareness regarding proper wound care among patients, increasing new product approval and launches, and others promote the U.S. chronic wound care market growth in the forthcoming years.

During the COVID-19 pandemic, the market witnessed slow growth due to reduced patient visits to hospitals and clinics and disruption in demand and supply chain.

LATEST TRENDS

Gradual Shift Toward Active Therapy is a Potential Trend in the Market  

There is a growing preference for bioactive therapies among patients and healthcare professionals to treat chronic wounds effectively. Bioactive therapies prevent tissue dehydration and promote a fast wound-healing process, making them suitable for chronic wounds. Furthermore, several research organizations and wound care product manufacturers are extensively investing in research and development to develop active therapies for treating chronic wounds.

• For instance, in July 2021, researchers from Michigan State University started developing biopolymer-based wound dressing to heal the injuries associated with diabetic foot ulcers.

DRIVING FACTORS

Rising Prevalence of Chronic Wounds to Augment the Demand for Advanced Dressings 

The country is witnessing a significant increase in the cases of chronic wounds, such as diabetes, foot ulcers, pressure ulcers, venous leg ulcers, and others. According to the report published in the American Academy of Home Care Medicine, an estimated 6.5 million people in the U.S. are affected by different types of chronic wounds annually.

Furthermore, government agencies and companies are launching awareness programs to promote adopting chronic wound care products for proper wound management and to prevent amputation in extreme cases. Such factors are projected to bolster the market growth in the upcoming years.

• For instance, in January 2022, Healogics, LLC. launched a program, “Healing can’t wait,” for the U.S. population suffering from chronic wounds. Through this program, the company raised awareness among the population of the importance of early diagnosis and treatment of chronic wounds.

RESTRAINING FACTORS

Rising Recalls of Wound Care Products to Limit the Market Growth

Despite the launches and approvals of various technologically advanced wound care products in the country, the increasing recalls of products owing to hampered product quality, manufacturing defects, and malfunctions are likely to hinder market growth.

• For instance, in June 2020, the U.S. FDA initiated a class II product recall for the ACTIV.A.C Therapy System developed by KCI USA, Inc. (now a part of 3M). The devices were recalled due to malfunctioning of the power supply, which resulted in the stoppage of negative pressure wound therapy without any notification.

Furthermore, the FDA mainly categorizes wound care products under the class II medical devices category. They are subject to general and special controls, making the approval process stringent. Thus, an increase in product recalls and stringent regulatory approval process hamper product adoption and limit market growth.

SEGMENTATION

By Type Analysis

Based on type, this market is segmented into diabetic foot ulcers, pressure ulcers, venous leg ulcers, and others. The diabetic ulcers segment accounted for the largest U.S. chronic wound care market share in 2022 and is projected to continue its dominance in the upcoming years. The increasing prevalence of uncontrolled diabetes leading to complications such as diabetic ulcers will likely increase the demand for chronic wound care products. Furthermore, the increase in the launch of various wound care products indicated to treat diabetic ulcers contributes to segment growth.

• For instance, according to a National Center for Biotechnology Information (NCBI) article published in August 2021, approximately 5.0% of the patient suffering from diabetes in the U.S. develop diabetic foot ulcers, and 1.0% of the patients undergo amputation due to severity.

According to the National Diabetes Statistics Report 2022, 37.3 million people in the U.S. had diabetes, of which approximately 51.0% were males and about 49.0% per females. Furthermore, according to an article published in the American Diabetes Association 2022, the lifetime risk of developing foot ulcers is about 19.0% to 34.0%.

By Product Analysis

Based on product, the market is categorized into advanced wound dressings, wound care devices, active therapy, and others. Advanced wound dressings held a dominant share due to their low cost and high efficiency in managing various wounds. Furthermore, the integration of advanced technology by the manufacturers to increase efficiency several times and promote faster wound healing is propelling their adoption among the healthcare professional, and patient population.

• For instance, in July 2019, Advanced Medical Solutions Group plc received U.S. FDA clearance for its silicone PHMB foam dressing and silver high-performance dressings. The silver dressing comprises next-generation antimicrobial gelling fiber technology to fasten healing in chronic wounds, such as diabetic foot ulcers and other ulcers.

By End User Analysis

Based on end user, the market is segmented into hospital & wound clinics and homecare settings & others. The homecare settings & others segment is expected to grow significantly during the forecast period. The rising preference among old age people to seek treatment at home, encourages the market players to launch wound care products that can be easily used in home care settings.

• For instance, in July 2022, Medela AG received FDA approval for Invia Ease Negative Pressure Wound Therapy (NPWT) System intended for chronic wounds, pressure ulcers, venous insufficiency ulcers, diabetic foot ulcers, and others. The device is designed to be used in acute and homecare settings.

KEY INDUSTRY PLAYERS

This market is consolidated, with major players like 3M, Smith & Nephew, and ConvaTec, Inc. occupying a dominant market share in 2022. The wide distribution network of these companies and a strong product portfolio for chronic wound care are the major factors responsible for their dominance. Furthermore, key players focusing on seeking approval and launching their innovative chronic wound care products in the U.S. market tend to strengthen their presence.

• For instance, in January 2023, Convatec Group Plc launched a foam dressing, ConvaFoam, integrated with super absorber technology. The dressing is developed to manage chronic wounds, such as pressure ulcers, diabetic foot ulcers, and venous leg ulcers, which are highly exuding.

Other market players include Integra LifeSciences Corporation, B. Braun Melsungen AG, Cardinal Health, Coloplast Corp, and Tissue Regenix, are also operating in the market. A strong emphasis by these companies on expanding their product offerings through mergers and acquisitions is anticipated to provide a strong foothold in the U.S. market.

LIST OF KEY COMPANIES PROFILED:

• Smith & Nephew (U.K.)


• Mölnlycke Health Care AB (Sweden)


• 3M (U.S.)


• ConvaTec Group PLC (U.K.)


• Tissue Regenix (U.S.)


• B. Braun Melsungen AG (Germany)


• Integra LifeSciences Corporation (U.S.)


• Coloplast Corp (Denmark)


• Cardinal Health (U.S.)


• MiMedx (U.S.)

KEY INDUSTRY DEVELOPMENTS: 

• November 2022- InfuSystem and Sanara MedTech Inc. partnered to form SI Wound Care, LLC, to deliver low-cost wound care solutions to improve patient outcomes. Through this partnership, InfuSystem will offer new NPWT products and expand its reach from hospitals to homecare settings.


• February 2022- Winner Medical received the U.S. FDA approval for its silver alginate dressing. Through this approval, the company aimed to expand its market in the U.S.


• January 2022- Convatec Group PLC entered into the wound biologics segment upon acquiring Triad LifeSciences, Inc.  Through this acquisition, the company strengthened its market position.

REPORT COVERAGE

The market report provides a detailed analysis of the market. It focuses on key aspects such as leading companies, product types, and leading applications of the product. Besides this, the report offers insights into the U.S. chronic wound care market trends and highlights key industry developments. In addition to the aforementioned factors, the report encompasses several factors that have contributed to the growth of the market over the recent years.

Report Scope & Segmentation